6-氯-5-氟吡啶-3-硼酸频那醇酯 | 1073312-28-3

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-氯-5-氟吡啶-3-硼酸频那醇酯
• 英文名称: 2-chloro-3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
• CAS: 1073312-28-3
• 化学式: C₁₁H₁₄BClFNO₂
• 分子量: 257.5
• InChiKey: QTSFEDRDXGFGKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.17
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  6-氯-5-氟吡啶-3-硼酸频那醇酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium phosphate 、 potassium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 52.0h， 生成 4-(4-(5-fluoro-6-(4-methylpiperazin-1-yl)pyridin-3-yl)quinazolin-6-yl)pyridin-2-amine
  参考文献：
  名称：

  SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF

  摘要：

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecule compounds having a 6,6-heterocyclic structure (e.g., compounds having a naphthyridine, pyrido-pyridazine, pyrido-pyrazine, quinoline, pyrazino-pyridazine, pyrimido-pyrimidine, quinazoline, quinoxaline or cinnoline ring system) which function as inhibitors of DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK3, CLK4, CDK7, CDK8/19, PI3K, PDGFrA/B, mTOR, WNT, homeodomain-interacting kinases (HIPKs), and/or CMGC kinases leading to inhibition of WNT signaling, and their use as therapeutics for the treatment of Alzheimer's disease, down syndrome, Parkinson's disease, Huntington's disease, diabetes, autoimmune diseases, inflammatory disorders (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer and metastatic colorectal cancer (e.g., metastatic colorectal cancer in the liver)), and other diseases.

  公开号：

  WO2023250082A2
• 作为产物：
  描述：

  2-氯-3-氟吡啶 、 联硼酸频那醇酯 在 (1,5-cyclooctadiene)(methoxy)iridium(I) dimer 、 4,4'-二叔丁基-2,2'-二吡啶 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 2-chloro-3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 、 6-氯-5-氟吡啶-3-硼酸频那醇酯
  参考文献：
  名称：

  METHODS FOR PRODUCING BORYLATED ARENES

  摘要：

  提供了一种选择性硼化芳烃的方法，包括带有电子吸引基团的芳烃（例如，1-氯-3-氟-2-取代苯）。在某些实施方式中，这些方法可以用来高效和区域选择性地制备硼化芳烃，而无需昂贵的低温反应条件。

  公开号：

  US20150065743A1

文献信息

• [EN] BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1<br/>[FR] DÉRIVÉS DE BENZAMIDE POUR INHIBER L'ACTIVITÉ D'ABL1, D'ABL2 ET DE BCR-ABL2
  申请人：NOVARTIS AG

  公开号：WO2013171640A1

  公开（公告）日：2013-11-21

  The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

  本发明涉及式(I)的化合物：其中Y、Y、R、R 2、R 3和R 4在发明摘要中有定义；能够抑制BCR-ABL1及其突变体的活性。本发明还提供了一种制备本发明化合物的方法，包括含有这种化合物的药物制剂以及使用这种化合物治疗癌症的方法。
• C–H Borylation Catalysts that Distinguish Between Similarly Sized Substituents Like Fluorine and Hydrogen
  作者：Susanne L. Miller、Ghayoor A. Chotana、Jonathan A. Fritz、Buddhadeb Chattopadhyay、Robert E. Maleczka、Milton R. Smith

  DOI：10.1021/acs.orglett.9b02299

  日期：2019.8.16

  By modifying ligand steric and electronic profiles it is possible to C–H borylate ortho or meta to substituents in aromatic and heteroaromatic compounds, where steric differences between accessible C–H sites are small. Dramatic effects on selectivities between reactions using B2pin2 or 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (HBpin) are described for the first time. Judicious ligand and borane combinations

  通过修改配体空间和电子分布，可以将 C-H 硼酸化为邻位或间位芳族和杂芳族化合物中的取代基，其中可及 C-H 位点之间的空间差异很小。首次描述了使用 B 2 pin 2或 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (HBpin)对反应之间选择性的显着影响。明智的配体和硼烷组合在底物上提供高度区域选择性的 C-H 硼酸化，而典型的硼酸化方案提供的选择性很差。
• COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1
  申请人：Furet Pascal

  公开号：US20150183801A1

  公开（公告）日：2015-07-02

  The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

  本发明涉及式(I)的化合物：其中Y，Y，R，R2，R3和R4在发明摘要中定义; 能够抑制BCR-ABL1及其突变体的活性。本发明还提供了一种制备本发明化合物的方法，包括这些化合物的制药制剂以及使用这些化合物治疗癌症的方法。
• Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
  申请人：Furet Pascal

  公开号：US09278981B2

  公开（公告）日：2016-03-08

  The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

  本发明涉及公式(I)的化合物：其中Y，Y，R，R2，R3和R4在本发明摘要中定义；能够抑制BCR-ABL1及其突变体的活性。 本发明还提供了一种制备本发明化合物的方法，包括这些化合物的制药制剂以及使用这些化合物治疗癌症的方法。
• Discovery and Evaluation of 3-Quinoxalin Urea Derivatives as Potent, Selective, and Orally Available ATM Inhibitors Combined with Chemotherapy for the Treatment of Cancer via Goal-Oriented Molecule Generation and Virtual Screening
  作者：Dexin Deng、Yingxue Yang、Yurong Zou、Kongjun Liu、Chufeng Zhang、Minghai Tang、Tao Yang、Yong Chen、Xue Yuan、Yong Guo、Shunjie Zhang、Wenting Si、Bin Peng、Qing Xu、Wen He、Dingguo Xu、Mingli Xiang、Lijuan Chen

  DOI：10.1021/acs.jmedchem.3c00082

  日期：2023.7.27

  important role in DNA damage response and is considered a potential target in cancer therapies. In this study, a goal-directed molecular generation approach based on ligand similarity and target specificity was applied to sample active molecules, and they were screened virtually to identify the theoretical lead compound 7a, which was later shown to inhibit ATM adequately. However, there is a main concern about

  ATM 在 DNA 损伤反应中发挥着重要作用，被认为是癌症治疗的潜在靶点。在这项研究中，基于配体相似性和靶标特异性的目标导向分子生成方法应用于活性分子样品，并对它们进行虚拟筛选，以鉴定理论先导化合物 7a ，后来证明该化合物可以充分抑制ATM。然而，人们主要担心其体外代谢稳定性差。随后进行了优化，以提高对 ATM 的效力和选择性，并减弱体外肝脏清除率，最终鉴定出10r具有纳摩尔级 ATM 抑制作用、对放疗和化疗药物优异的细胞敏感性以及令人印象深刻的药代动力学特征。此外，10r与伊立替康联合在SW620异种移植模型中表现出协同抗肿瘤功效，表明它可能是一种有前途的联合化疗治疗癌症的候选药物。